Patient leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986

This medicine is dispensed with a doctor's prescription only

TAKHZYRO

Solution for subcutaneous injection in a pre-filled syringe

Composition:

Active ingredient and its quantity: lanadelumab 300 mg/2 ml.

Inactive ingredients: see section 6.

Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours.

1. WHAT IS THIS MEDICINE INTENDED FOR?

Takhzyro is intended for use in adults and adolescents aged 12 years and older to prevent angioedema attacks in patients with hereditary angioedema (HAE).

Therapeutic group: Other hematological agents, medicines used for hereditary angioedema.

What hereditary angioedema (HAE) is

HAE is an inherited condition which runs in families. With this condition your blood does not contain enough of a protein called 'C1 inhibitor', or C1 inhibitor does not work properly. This leads to too high level of 'plasma kallikrein', which in turn produces higher levels of bradykinin in your blood. Too high levels of bradykinin lead to symptoms of HAE like swelling and pain in the,

- hands and feet
- face, eyelids, lips or tongue
- voice-box (larynx), which may cause difficulty breathing
- genitals

How Takhzyro works

Takhzyro is a type of protein that blocks the activity of plasma kallikrein. This helps to reduce the amount of bradykinin in your bloodstream and prevents symptoms of HAE.

2. <u>BEFORE USING THE MEDICINE</u>

Do not use this medicine if:

you are sensitive (allergic) to the active ingredient – lanadelumab, or to any of the other ingredients of this medicine (see the list of inactive ingredients in section 6).

Special warnings regarding use of the medicine

- Talk to your doctor, pharmacist or nurse before using Takhzyro.
- If you have a severe allergic reaction to Takhzyro with symptoms such as a rash, tightness in the chest, wheezing, or a fast heartbeat, tell your doctor, pharmacist or nurse **immediately**.

Children and adolescents

There is no information regarding safety and efficacy of using this medicine in children under 12 years of age.

Laboratory tests and follow up

Tell your doctor if you are using Takhzyro before you have laboratory tests intended to measure how well your blood is clotting. This is because Takhzyro in your blood may interfere with some laboratory tests, leading to inaccurate results.

Drug interactions

If you are taking, or have recently taken, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or pharmacist.

Takhzyro is not known to affect other medicines or be affected by other medicines.

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, think you are pregnant or are planning to become pregnant, ask your doctor or pharmacist for advice before starting to use Takhzyro.

There is limited information on the safety of Takhzyro use during pregnancy and breastfeeding. As a precautionary measure, it is preferable to avoid the use of lanadelumab during pregnancy. Use during breastfeeding may be allowed at doctor's discretion.

Driving and using machines

This medicine has negligible influence on the ability to drive or use machines.

Important information about some of this medicine's ingredients

The medicine contains less than 1 mmol sodium (23 mg) per ml of solution; that is to say essentially 'sodium-free'.

3. HOW SHOULD YOU USE THE MEDICINE?

Takhzyro is provided in single-use pre-filled syringes as ready-to-use solution. Your treatment will be started and managed under the supervision of a doctor experienced in the care of patients with HAE.

Always use this medicine according to your doctor's instructions. Check with your doctor or pharmacist if you are not sure about your dose or about how to take this medicine.

The dosage and treatment regimen will be determined by the doctor only. Usually, the recommended dosage is:

The recommended starting dose is 300 mg every 2 weeks. If you have not had an attack for a long period, your doctor may change the dose to 300 mg every 4 weeks, especially if you have a low body weight.

How to inject the medicine

If you inject the medicine yourself or if your caregiver injects it, you or your caregiver must carefully read and follow the instructions in section 7, "Instructions for use".

- Takhzyro is intended for injection under the skin ('subcutaneous injection').
- The injection can be given either by yourself or a caregiver.
- A doctor, pharmacist or nurse should show you how to prepare and inject the medicine properly before you use Takhzyro for the first time. Do not inject yourself or someone else until you have been trained to inject the medicine.
- Insert the needle into the fatty tissue in the abdomen, thigh or upper arm.
- Inject the medicine in a different place each time.
- Use each pre-filled syringe of Takhzyro only once.

Do not exceed the recommended dose.

If you have accidentally taken a higher dose of Takhzyro than necessary

If you have taken an overdose or if a child has accidentally swallowed the medicine, immediately contact a doctor or proceed to a hospital emergency room and bring the package of the medicine with you.

If you forgot to take this medicine

If you miss a dose of Takhzyro, inject your dose as soon as possible, but there must be at least a 10 day interval between the doses. If you are not sure when to inject Takhzyro after a missed dose, ask your doctor, pharmacist or nurse.

Adhere to the treatment regimen recommended by your doctor.

Even if you feel better, do not stop taking this medicine without consulting your doctor.

Do not take medicines in the dark! Check the label and dose <u>each time</u> you take medicine. Wear glasses if you need them.

If you have any further questions about using this medicine, consult your doctor or pharmacist.

4. SIDE EFFECTS

As with any medicine, using Takhzyro may cause side effects in some users. Do not be alarmed when reading the list of side effects; you may not experience any of them.

If you have a severe allergic reaction to Takhzyro with symptoms such as a rash, tightness in the chest, wheezing, or a fast heartbeat, **contact your doctor immediately.**

Tell your doctor, pharmacist or nurse if you notice any of the following side effects:

Very common side effects (may occur in more than 1 in 10 patients):

Injection site reactions – symptoms include pain, skin redness, bruising, discomfort, swelling, bleeding, itching, hardening of skin, tingling, warmth and rash.

Common side effects (may occur at a frequency of up to 1 in 10 patients):

- Allergic reactions including itching, discomfort and tingling of the tongue
- · Dizziness, feeling faint
- · Raised skin rash
- Muscle pain
- Blood tests showing liver changes

If you experience any side effect, if any side effect gets worse, or if you experience a side effect not mentioned in this leaflet, consult your doctor.

Side effects can be reported to the Ministry of Health by clicking on the link "Reporting side effects following drug treatment" found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link:

https://sideeffects.health.gov.il/

5. HOW TO STORE THE MEDICINE?

- Avoid poisoning! This medicine and any other medicine must be kept in a safe place out of the reach and sight of children and/or infants in order to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the doctor.
- Do not use the medicine after the expiry date (exp. date) that appears on the package. The expiry date refers to the last day of that month.

Storage conditions

- Store in a refrigerator (2°C-8°C). Do not freeze. Keep the pre-filled syringe in the outer carton package in order to protect from light.
- The pre-filled syringe may be stored below 25°C for a single period of 14 days, but not beyond the expiry date. Do not return Takhzyro to refrigerated storage after storage at room temperature.
- Do not use this medicine if you notice signs of deterioration in the appearance of the medicine such as particles in the pre-filled syringe or changed color of the injection solution.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

6. ADDITIONAL INFORMATION

In addition to the active ingredient, this medicine also contains non-active ingredients:

Water for injections, L-Histidine, Sodium chloride, Sodium phosphate dibasic (dihydrate), Citric acid monohydrate, Polysorbate 80.

What the medicine looks like and contents of the pack

Takhzyro is presented as a clear, colorless to slightly yellow solution for injection in a pre-filled syringe. The pack may contain:

- One pre-filled syringe (2 ml/syringe) in a carton
- Two pre-filled syringes (2 ml/syringe) in a carton
- A pack containing 3 cartons, each carton containing two pre-filled syringes (2 ml/syringe), a total of 6 pre-filled syringes.

Not all pack sizes may be marketed.

License holder's name and address: Takeda Israel Ltd., 25 Efal St., Petach Tikva 4951125.

Manufacturer's name and address:

Takeda Pharmaceuticals International AG Ireland Branch, Block 3 Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland.

7. INSTRUCTIONS FOR USE

Make sure that you read, understand and follow the step-by-step instructions for injecting Takhzyro. Contact your doctor, pharmacist or nurse if you have any questions.

Do not shake Takhzyro.

Parts of your Takhzyro pre-filled syringe Before Use (Figure A).




Figure A

STEP 1: Prepare for your injection

A. Take an alcohol swab, cotton ball/gauze pad, adhesive bandage and a sharps disposal container (**Figure B**) and place on a clean, flat, surface in a well-lit area. These supplies are not included in the Takhzyro packaging.



Figure B

- B. Remove Takhzyro from the refrigerator, open the carton box and remove the Takhzyro pre-filled syringe from the tray.
 - **Do not** use the Takhzyro pre-filled syringe if the tamper evident seal is open or broken.
 - Before you prepare your injection, allow the pre-filled syringe to reach room temperature for at least 15 to 30 minutes.
 - Your medicine is sensitive to warm temperatures. **Do not** use external heat sources such as hot water to warm your Takhzyro pre-filled syringe.
 - Do not remove the needle cap until you are ready to inject.
- C. Wash your hands with soap and water. Dry your hands completely (**Figure C**).



Figure C

- D. Check the expiration date on the label (Figure D).
 - **Do not** use Takhzyro pre-filled syringe if the expiration date has passed.




Figure D

- E. **Visually inspect (with your eyes)** the Takhzyro pre-filled syringe for any sign of damage and make sure the medicine is colourless to slightly yellow.
 - **Do not** use product if syringe is damaged e.g., cracked.
 - **Do not** inject if the medicine is discoloured, cloudy or has flakes or particles in it and call your

doctor, nurse or pharmacist.

 You might see bubbles in the Takhzyro pre-filled syringe. This is normal and will not affect your dose

STEP 2: Select and prepare your injection site

- A. The Takhzyro pre-filled syringe should be injected into your stomach, thigh, or the back of the upper arm (the outer area of the upper arm is not recommended if you are injecting yourself) (**Figure E**).
 - It is important to inject into different sites to keep skin healthy. Each new injection should be given at least 3 cm from the last injection site.
 - Do not inject into an area of your body where the skin is irritated, reddened, bruised, or infected.
 - The injection site you choose should be at least 5 cm away from any scars or your navel.





Figure E

- B. Clean the injection site with an alcohol swab and allow it to dry completely.
 - **Do not** fan or blow air on the clean site
 - **Do not** touch this area again before giving your injection.
- C. Remove needle cap from the Takhzyro pre-filled syringe. Gently pull the needle cap straight off with one hand, and firmly hold the middle of the pre-filled syringe with the other hand. Throw away the needle cap (**Figure F**).
 - Do not recap your pre-filled syringe.
 - **Do not** use the pre-filled syringe if it has been dropped without the cap on or if the needle looks damaged or bent.
 - **Do not** touch the needle or allow the needle to touch anything.



STEP 3: Inject Takhzyro

A. Grip the pre-filled syringe in one hand like a pencil. Avoid touching the needle or pushing on the plunger (**Figure G**).



Figure G

- B. With your other hand, gently pinch about 3 cm fold of skin at the cleaned injection site.
- C. With one quick, short motion, push needle all the way into skin. Make sure to keep the needle in place (**Figure H**).




Figure H

- D. Slowly push the plunger until all of the liquid is injected and the syringe is empty, then gently let go of your skin.
- E. Slowly withdraw needle while maintaining the syringe at the same angle (**Figure I**).




Figure I

- F. Press cotton ball or gauze pad over injection site if needed and hold for 10 seconds.
 - **Do not** rub the injection site. You may have minor bleeding. This is normal.
 - Cover injection site with an adhesive bandage if needed.
- G. Throw away your used Takhzyro pre-filled syringe.
 - **Do not** touch the needle.
 - To avoid a needle-stick injury, **do not** recap the needle.
 - Put your pre-filled syringes in a sharps disposal container right away after use.
 - **Do not** reuse the pre-filled syringe and any of your injection supplies.

Important: Always keep the sharps disposal container out of the reach of children.

This leaflet was updated according to MOH guidelines in: October 2021 Registration number of the medicine in the Ministry of Health's National Drug Registry: 163-47-35885-00.